|
Delayed
Toronto S.E.
14:27:32 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 36.92 CAD | +1.37% |
|
+5.91% | +13.95% |
| 08:50am | AbbVie Presents New Data Across Lung Cancer Pipeline At WCLC 2026 | CI |
| 08-20 | Piper Sandler Adjusts Price Target on AbbVie to $303 From $298, Maintains Overweight Rating | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- ABBV Stock
- ABBV Stock
- Consensus AbbVie Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
